Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)
Jensen C, Thiry A, Kim E, Lovergren M, Croop R, Coric V, L‘Italien G, Lipton R. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.873.Peer-Reviewed Original Research